The Effects of Weight Reduction in IgA Nephropathy

Chulalongkorn University30 enrolled

Overview

The study aims to explore the non-pharmacological treatment of IgA nephropathy by weight reduction. The investigators hypothesized that benefits of weight loss may reduce proteinuria.

This is a prospective randomized study in adult IgA nephropathy. The investigators enrolled 30 patients who have proteinuria exceeds 1 g per day with biopsy proven IgA nephropathy. The experimental arm recieves the non-pharmacological treatment, weight reduction protocol. All patients in this arm must be reduce their body weight in 3-5 % from baseline as protocol. Another arm is control group which recieves standard treatment of IgA nephropathy including ACEIs/ARBs for blood pressure control (target \< 130/80 mmHg). The primary outcome is proteinuria level. The secondary outcome is cytokines and inflammatory markers level including interleukin-6, resistin, adiponectin, leptin and monocyte chemoattractant protein-1.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Proteinuria

Interventions

weight reductionBEHAVIORAL

1. Set target daily energy requirement by nutritionist (25-30 Kcal/Kg/day minus 500 Kcal) 2. Advice and encourage patients to do aerobic exercise at least 30 minutes/day for 4-5 days/weeks. 3. Daily body weight measurement. 4. Record food diary

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Biopsy-proven IgA nephropathy * body mass index more than 23 Kg/m2 * 24 hours urine protein more than 1 g * estimated GFR more than 20 ml/min Exclusion Criteria: * pregnancy and lactation * rapidly renal function decline * crescent formation in renal biopsy more than 10%

Locations (1)

Faculty of medicine, Chulalongkorn university

Bangkok, Bangkok, Thailand

RECRUITING

Outcomes

Primary Outcomes

Percentage change of 24-hour proteinuria

The investigators measure amount of 24-hour proteinuria at randomization peroid ( as baseline), first, third and sixth month. Then, investigators calculate the percentage reduction of proteinuria at different time points.

Time frame: 6 months

Secondary Outcomes

plasma concentration of IL-6, adiponectin, resistin, leptin, MCP-1

The investigators measure amount of plasma concentration of IL-6, adiponectin, resistin, leptin, MCP-1 at randomization peroid ( as baseline) and sixth month. Then, investigators calculate the percentage reduction of these cytokines in 6 months peroid.

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.